Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round.

Curevo has set its sights on competing with GSK’s shingles vaccine dominance by securing $110m and securing a former ...

Amezosvatein has shown excellent immunogenicity and improved tolerability in Phase 2 study -- Medicxi leads round, joined by ...

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

Jose Cuervo, the world’s top-selling tequila brand, says it is not a supporter of the additive-free campaign that has swept ...

Reserva de la Familia hires a new Mexican artist to design the artwork for the Extra Añejo collector’s box. The post Reserva de la Familia by Jose Cuervo is launching its 2025 Collector’s Box appeared ...

MEXICO CITY, Feb 27 (Reuters) - Mexico's Becle (CUERVO.MX), opens new tab, the maker of Jose Cuervo tequila, warned on Thursday that it could face an $80 million impact this year if U.S. President ...

Concurrent with the round, Moncef Slaoui, PhD, will join Curevo as Board Chair. Dr. Slaoui was most recently the Chief Scientific Advisor to Operation Warp Speed during the COVID-19 pandemic ...

Former Chair of GSK’s vaccine business and Chief Scientific Advisor to Operation Warp Speed, Moncef Slaoui, to join Curevo as Board Chair SEATTLE, March 17, 2025 (GLOBE NEWSWIRE) -- Curevo ...